Mr. Boschwitz brings extensive strategic marketing experience to Orchid
Cellmark. Most recently, he served as Director of Marketing, Planning,
Analysis and Research at Quest Diagnostics, for the company's physician
diagnostics business division. As part of that role, Mr. Boschwitz was
responsible for development of the marketing plan and optimizing sales force
effectiveness. Previously, Mr. Boschwitz was a Principal in
About Orchid Cellmark
Orchid Cellmark is a leading provider of identity DNA testing services for the human identity and agriculture markets. In the human identity area, the company provides DNA testing services for forensic, family relationship and security applications. In the agriculture field, Orchid Cellmark provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the world-renowned Cellmark brand that has been associated with exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchid.com.
All statements in this press release that are not historical are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are subject to the risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, risks and uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of Orchid Cellmark's products and services, dependence on government
funding and collaborations, regulatory approvals, competition, intellectual
property of others, patent protection, litigation, the timing of release of
federal funds, the timing and amount of contracts put up for bid, and Orchid
Cellmark's ability to successfully offer its services directly to U.K. police
forces. These risks and other additional factors affecting these forward-
looking statements and Orchid Cellmark's business are discussed under the
headings "Risks Related to Our Business" and "Risks Associated with Our Common
Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended
Contacts Investor Relations: Media: Mary Bashore Barbara Lindheim Orchid Cellmark Inc. GendeLLindheim BioCom Partners (609) 750-2324 (212) 918-4650
SOURCE Orchid Cellmark Inc.